Sector News

Roche buys France’s Trophos in 470 million euro deal

January 16, 2015
Life sciences
Roche has hit the acquisition trail to buy France’s Trophos in a deal that could be worth 470 million euros.
 
Trophos, a privately-held biotech based in Marseille, France, has developed olesoxime, which is being developed for spinal muscular atrophy – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a Phase II trial have shown a beneficial effect on the maintenance of neuromuscular function and a reduction in medical complications associated with the disease.
 
Under the terms of the agreement, Trophos’ shareholders will receive 120 million euros upfront and up to 350 million euros based on achievement of predetermined milestones.
 
Roche’s chief medical officer Sandra Horning said “we will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible”. The compound has orphan drug status on both sides of the Atlantic.
 
The deal rounds off a busy week for Roche, which has paid over $1 billion to acquire a majority stake in molecular information company Foundation Medicine. The Swiss giant licensed an early-stage treatment for antibiotic resistance from Japan’s Meiji Seika Pharma and Fedora of Canada in a deal that could be worth $750 million.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach